IDH-mutation is a weak predictor of long-term survival in glioblastoma patients

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Amelot, Aymeric ^a   De Cremoux, Patricia ^b   Quillien, Véronique ^c   Polivka, Marc ^a   Adle Biassette, Homa ^a   Lehmann Che, Jacqueline ^b   Françoise, Laurence ^b   Carpentier, Antoine F ^d   George, Bernard ^a,e   Mandonnet, Emmanuel ^a,e,f   Froelich, Sébastien ^a,e  

^a HÔPITAL LARIBOISIÈRE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d AVICENNE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DNA LIGASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; EXON; FEMALE; FRANCE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PROCEDURES; GLIOBLASTOMA; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUTATION RATE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PROMOTER REGION; RETROSPECTIVE STUDY; SANGER SEQUENCING; SURVIVAL TIME; TREATMENT DURATION; AGED; BRAIN NEOPLASMS; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; SURVIVOR; TIME FACTOR;

ADULT; AGED; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84941331387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130596     Document Type: Article

References (45)

1. Omuro A, De Angelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310: 1842-1850. doi: 10.1001/jama.2013.280319 PMID: 24193082
2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773. doi: 10.1056/NEJMoa0808710 PMID: 19228619
3. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011; 103: 143-153. doi: 10.1093/jnci/djq497 PMID: 21163902
4. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010; 75: 1560-1566. doi: 10.1212/WNL.0b013e3181f96282 PMID: 20975057
5. Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012; 110: 325-333. doi: 10.1007/s11060-012-0977-2 PMID: 23015095
6. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27: 4150-4154. doi: 10.1200/JCO.2009.21.9832 PMID: 19636000
7. Song Tao Q, Lei Y, Si G, Yan Qing D, Hui Xia H, Xue Lin Z, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012; 103: 269-273. doi: 10.1111/j.1349-7006.2011.02134.x PMID: 22034964
8. Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS ONE. 2012; 7: e30339. doi: 10.1371/journal.pone.0030339 PMID: 22291938
9. Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS ONE. 2013; 8: e68782. doi: 10.1371/journal.pone.0068782 PMID: 23894344
10. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013; 19: 5146-5157. doi: 10.1158/1078-0432.CCR-13-0017 PMID: 23918605
11. Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro-oncology. 2014; 16: 1186-1195. doi: 10.1093/neuonc/nou043 PMID: 24662514
12. Louis D, Ohgaki H, Wiestler O, Cavanee W. WHO Classification of Tumors of the Central Nervous System. Lyon: IARC; 2007.
13. Loussouarn D, Le Loupp A-G, Frenel J-S, Leclair F, Von Deimling A, Aumont M, et al. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol. 2012; 40: 2058-2062. doi: 10.3892/ijo.2012.1404 PMID: 22447191
14. Frenel JS, Leux C, Loussouarn D, Le Loupp A-G, Leclair F, Aumont M, et al. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. J Neurooncol. 2013; 114: 85-91. doi: 10.1007/s11060-013-1152-0 PMID: 23681562
15. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, Methy Light, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012; 118: 4201-4211. doi: 10.1002/cncr.27392 PMID: 22294349
16. Quillien V, Lavenu A, Sanson M, Legrain M, Dubus P, Karayan-Tapon L, et al. Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol. 2014; 116: 487-496. doi: 10.1007/s11060-013-1332-y PMID: 24420923
17. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107: 359-364. doi: 10.1007/s11060-011-0749-4 PMID: 22045118
18. Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-oncology. 2012; 14: 1178-1184. doi: 10.1093/neuonc/nos153 PMID: 22869622
19. Vertosick FT, Selker RG. Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol. 1992; 38: 359-363. PMID: 1336626
20. McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer. 2003; 98: 1745-1748. doi: 10.1002/cncr.11666 PMID: 14534892
21. Johnson DR, Ma DJ, Buckner JC, Hammack JE. Conditional probability of long-term survival in glioblastoma: a population-based analysis. Cancer. 2012; 118: 5608-5613. doi: 10.1002/cncr.27590 PMID: 22569786
22. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain. 2007; 130: 2596-2606. doi: 10.1093/brain/awm204 PMID: 17785346
23. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg. 2004; 101: 219-226. doi: 10.3171/jns.2004.101.2.0219 PMID: 15309911
24. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol. 1999; 46: 183-188. PMID: 10443883
25. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27: 5743-5750. doi: 10.1200/JCO.2009.23.0805 PMID: 19805672
26. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res. 2002; 8: 180-187. PMID: 11801556
27. Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro-oncology. 2011; 13: 1339-1348. doi: 10.1093/neuonc/nor133 PMID: 21914639
28. Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, et al. Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol. 2011; 104: 351-356. doi: 10.1007/s11060-010-0500-6 PMID: 21221714
29. Barnholtz-Sloan JS, Maldonado JL, Williams VL, Curry WT, Rodkey EA, Barker FG, et al. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol. 2007; 85: 171-180. doi: 10.1007/s11060-007-9405-4 PMID: 17530174
30. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, De Monte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95: 190-198. doi: 10.3171/jns.2001.95.2.0190
31. Scoccianti S, Magrini SM, Ricardi U, Detti B, Buglione M, Sotti G, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology). Neurosurgery. 2010; 67: 446-458. doi: 10.1227/01.NEU.0000371990.86656.E8 PMID: 20644432
32. Thumma SR, Fairbanks RK, Lamoreaux WT, Mackay AR, Demakas JJ, Cooke BS, et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012; 10: 75. doi: 10.1186/1477-7819-10-75 PMID: 22553975
33. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003. doi: 10.1056/NEJMoa043331 PMID: 15758010
34. Cheng H-B, Yue W, Xie C, Zhang R-Y, Hu S-S, Wang Z. IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis. Tumour Biol. 2013; 34: 3555-3559. doi: 10.1007/s13277-013-0934-5 PMID: 23904262
35. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci. 2011; 18: 66-70. doi: 10.1016/j.jocn. 2010.04.050 PMID: 20888234
36. Kreth F-W, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013; 24: 3117-3123. doi: 10.1093/annonc/mdt388 PMID: 24130262
37. Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-oncology. 2014; 16: 610-611. doi: 10.1093/neuonc/not312 PMID: 24637551
38. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996. doi: 10.1056/NEJMoa043330 PMID: 15758009
39. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812. doi: 10.1126/science.1164382 PMID: 18772396
40. Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, et al. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer. 2014; 135: 1822-1831. doi: 10.1002/ijc.28836 PMID: 24615357
41. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon J-G, et al. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS ONE. 2011; 6: e16146. doi: 10.1371/journal.pone.0016146 PMID: 21249131
42. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013; 31: 4085-4091. doi: 10.1200/JCO.2013.49.6968 PMID: 24101040
43. Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JWM, Boots-Sprenger SHE, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-oncology. 2014; 16: 1263-1273. doi: 10.1093/neuonc/nou005 PMID: 24510240
44. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol. 2007; 83: 91-93. doi: 10.1007/s11060-006-9292-0 PMID: 17164975
45. Zhang K, Wang X, Zhou B, Zhang L. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer. 2013; 12: 449-458. doi: 10.1007/s10689-013-9607-1 PMID: 23397067